| 13.1 -0.24 (-1.8%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.07 | 1-year : | 17.47 |
| Resists | First : | 13.76 | Second : | 14.96 |
| Pivot price | 13.5  |
|||
| Supports | First : | 11.82 | Second : | 9.84 |
| MAs | MA(5) : | 13.76 |
MA(20) : | 13.34 |
| MA(100) : | 13.32 |
MA(250) : | 11.15 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 46.5 |
D(3) : | 60.3 |
| RSI | RSI(14): 45.9 |
|||
| 52-week | High : | 20.5 | Low : | 6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GHRS ] has closed above bottom band by 32.5%. Bollinger Bands are 34.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.63 - 13.73 | 13.73 - 13.8 |
| Low: | 12.6 - 12.72 | 12.72 - 12.82 |
| Close: | 12.93 - 13.1 | 13.1 - 13.23 |
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Mon, 29 Sep 2025
H.C. Wainwright maintains buy on GH Research stock, $40 target - MSN
Fri, 12 Sep 2025
GH Research to Join TD Cowen Neuropsychiatry Summit - TipRanks
Wed, 10 Sep 2025
Cantor Fitzgerald reiterates Overweight rating on GH Research stock - Investing.com
Tue, 09 Sep 2025
GH Research Presents Promising Trial Results for GH001 at ISBD 2025 - TipRanks
Tue, 02 Sep 2025
GH Research PLC (GHRS) Reports 73% Remission in Phase 2b Depression Trial - Yahoo Finance
Wed, 23 Jul 2025
GH Research Announces Global Pivotal Program Plans and Further Development Updates - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 31.4 (%) |
| Held by Institutions | 70.4 (%) |
| Shares Short | 1,930 (K) |
| Shares Short P.Month | 2,290 (K) |
| EPS | -0.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -12.8 % |
| Return on Equity (ttm) | -16.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -40 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -17.95 |
| PEG Ratio | 0 |
| Price to Book value | 2.67 |
| Price to Sales | 0 |
| Price to Cash Flow | -20.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|